Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Rigosertib

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Rigosertib?

Rigosertib is an investigational drug.

There have been 29 clinical trials for Rigosertib. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1^st 2013.

The most common disease conditions in clinical trials are Preleukemia, Myelodysplastic Syndromes, and Syndrome. The leading clinical trial sponsors are Onconova Therapeutics, Inc., Bristol-Myers Squibb, and Icahn School of Medicine at Mount Sinai.

Summary for Rigosertib

US Patents	0
International Patents	0
US Patent Applications	441
WIPO Patent Applications	386
Japanese Patent Applications	110
Clinical Trial Progress	Phase 3 (2013-08-01)
Vendors	32

Recent Clinical Trials for Rigosertib

Title	Sponsor	Phase
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC	Onconova Therapeutics, Inc.	Early Phase 1
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC	Thomas Jefferson University	Early Phase 1
Rigosertib for RDEB-SCC	Prof. Johann Bauer	Phase 1/Phase 2

See all Rigosertib clinical trials

Clinical Trial Summary for Rigosertib

Top disease conditions for Rigosertib

Top clinical trial sponsors for Rigosertib

See all Rigosertib clinical trials

US Patents for Rigosertib

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign up for a Free Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys

Mallinckrodt

Medtronic

Harvard Business School

Johnson and Johnson

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.